Neurosurgery research at Penn medicine covers all of the key topics in the neurosciences from basic science research to clinical trials. The department is home to a rich number of laboratories focusing on issues including spinal biomechanics, neurotrauma, neurodegenerative disorders, brain tumors and traumatic brain injury.
H. Isaac Chen MD
is interested in developing novel methods for restoring brain circuitry after injury. His lab combines principles from stem cell biology, neural tissue engineering, and neural interface technologies to generate complex neural tissues. The lab also examines how this tissue integrates with brain networks following transplantation.
Lucas Translational Neuromodulation Laboratory
Timothy Lucas, MD is the Director of the Translational Neuromodulation Laboratory and Associate Director of the Center For Neuro-Engineering and Therapeutics. His lab develops implantable brain-computer interface devices to bypass or augment damaged neural connections as a treatment for paralysis. They also examine decoding strategies for electrocorticography in human BCI applications.
Neuro-Oncology research on a host of topics is being conducted by several of Penn Neurosurgery faculty. Donald O'Rourke, MD, is interested in the cell and molecular biology of erbB family receptor tyrosine kinases. Leslie Sutton, MD, has research interests in the areas of brain tumor treatment and biology, and fetal surgery. James Schuster, MD, PhD, is especially interested in treatment of metastatic involvement of the spine from other primary tumors including lung, breast, renal, and prostate cancer.
The Smith Neurotrauma Laboratory’s main research focus centers on the study of the mechanisms and progressive degenerative damage that occurs with brain trauma. Specific concentration is paid to the nerve fibers in the brain, or axons, which are vulnerable to trauma.
The research focus of the Watson laboratory centers on understanding the mechanisms that underlie traumatic brain injury and the development of potential therapeutic treatment strategies.
Resnick and Storm Laboratories
The Resnick and Storm Laboratories at the Children’s Hospital of Philadelphia focus on defining the molecular mechanisms underlying pediatric brain tumors. Their research studies the characterization of the genetic abnormalities defining pediatric tumors, the development of model systems recapitulating the disease process and cell signaling alterations, and ultimately on defining and testing targeted therapies.
The Siman laboratory studies mechanisms and markers for neurodegenerative disorders. The laboratory developed an antibody-based technology known as protease fingerprinting for measuring activation of specific proteases associated with cell death signaling. This technology led to the identification of biomarkers that are measurably increased in cerebrospinal fluid and blood following brain injury in both experimental animals and human patients, and indicate the magnitude of the brain damage, the underlying signaling mechanisms involved, and the efficacy of candidate neuroprotective treatment regimens. By developing a panel of markers for neurodegeneration and immunoassays for their simple yet highly sensitive quantitation, we aim to impact the diagnosis, prognosis, and treatment of acute and chronic brain damage in numerous clinical settings.
The mission of the Cullen Lab is to develop cutting-edge bioengineering strategies to restore neurological function following neurotrauma or neurodegenerative disease. The Cullen Lab has pioneered tissue engineered “living scaffolds” to promote neural regeneration, micro-tissue engineering to restore brain circuitry, and living biological electrodes for brain-machine interface and neuromodulation. To complement these efforts, the Cullen Lab is also working to improve our understanding of traumatic brain injury, with emphasis on injury biomechanics, neuronal biophysical responses, and neurodegenerative pathways.
The focus of the Translational Spine Research Laboratory is the pathophysiology and treatment of degenerative and developmental disorders affecting the spine, particularly those affecting the intervertebral discs and vertebral bones. Dr. Lachlan Smith and Dr. Neil Malhotra use cutting edge techniques in molecular biology, biochemistry and bioengineering, coupled with novel in vitro model systems to study disease mechanisms. This research in the translational space bridges the fields of tissue engineering, biomaterials, drug delivery and stem cells, and is focused on arresting disease progression, restoring spine function and potentiating long term tissue regeneration.